Evidence map›Paper›PMID 34739220›Full record

ArticleAnalytical chemistry2021

Affinity Capillary Electrophoresis-Mass Spectrometry as a Tool to Unravel Proteoform-Specific Antibody-Receptor Interactions.

Christoph Gstöttner, Michaela Hook, Tony Christopeit, Alexander Knaupp, Tilman Schlothauer, Dietmar Reusch, Markus Haberger, Manfred Wuhrer, Elena Domínguez-Vega

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. [Annual review of capillary electrophoresis technology in 2021].Se pu = Chinese journal of chromatography · 2022
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Christoph GstöttnerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2333ZA, The Netherlands.
Michaela HookPharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg 82377, Germany.
Tony ChristopeitPharma Research and Early Development, Roche Innovation Center Munich, Penzberg 82377, Germany.
Alexander KnauppPharma Research and Early Development, Roche Innovation Center Munich, Penzberg 82377, Germany.
Tilman SchlothauerPharma Research and Early Development, Roche Innovation Center Munich, Penzberg 82377, Germany.
Dietmar ReuschPharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg 82377, Germany.
Markus HabergerPharma Technical Development Penzberg, Roche Diagnostics GmbH, Penzberg 82377, Germany.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2333ZA, The Netherlands.ORCID 0000-0002-0814-4995
Elena Domínguez-VegaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2333ZA, The Netherlands.ORCID 0000-0002-6394-0783
Roche Pharma AG (Germany) · DELeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibody (mAb) pharmaceuticals consist of a plethora of different proteoforms with different functional characteristics, including pharmacokinetics and pharmacodynamics, requiring their individual assessment. Current binding techniques do not distinguish between coexisting proteoforms requiring tedious production of enriched proteoforms. Here, we have developed an approach based on mobility shift-affinity capillary electrophoresis-mass spectrometry (ACE-MS), which permitted us to determine the binding of coexisting mAb proteoforms to Fc receptors (FcRs). For high-sensitivity MS analysis, we used a sheathless interface providing adequate mAb sensitivity allowing functional characterization of mAbs with a high sensitivity and dynamic range. As a model system, we focused on the interaction with the neonatal FcR (FcRn), which determines the half-life of mAbs. Depending on the oxidation status, proteoforms exhibited different electrophoretic mobility shifts in the presence of FcRn, which could be used to determine their affinity. We confirmed the decrease of the FcRn affinity with antibody oxidation and observed a minor glycosylation effect, with higher affinities for galactosylated glycoforms. Next to relative binding, the approach permits the determination of individual

Indexed as

Electrophoresis, CapillaryReceptors, FcAntibodies, MonoclonalGlycosylationHistocompatibility Antigens Class IHumansInfant, NewbornMass SpectrometryAntibodies, MonoclonalHistocompatibility Antigens Class IReceptors, Fc

Identifiers

PMID34739220
PMCPMC8600502
OpenAlexW3210573823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.